Key facts
- It has raised $28.9M across 3 recorded rounds; the latest was Early Stage VC ($11.5M) in Apr 2022.
- Notable investors include National Institutes of Health, University of California, National Aeronautics and Space Administration, Advanced MedTech Holdings, BioVentures Investors — 13 tracked in total.
- Sonomotion has filed 4 Form Ds with the SEC since 2016, most recently Apr 2022 ($11.5M sold to 4 investors).
- Status: Privately Held (backing).
Investors
13+- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Sonomotion
Funding rounds
3 roundsAbout Sonomotion
Developer of a non-invasive medical device intended to offer a method for kidney stone treatment. The company's device fragments large kidney stones safely and effectively, and clears the resulting stone fragments and also without general anesthesia or x-ray radiation, enabling caregivers to get access to an innovative procedure to treat patients with kidney diseases in a cost-efficient way.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2014
- Employees
- 9
- Website
- sonomotion.com/
- Ownership
- Privately Held (backing)
Sonomotion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sonomotion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sonomotion in its N-PORT filings yet. We sweep new filings monthly.